Trial Profile
A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL SYNDROME.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2014
Price :
$35
*
At a glance
- Drugs OMS 210 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Lotus Pharmaceuticals
- 16 Aug 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 14 Jul 2012 Planned number of patients changed from 228 to 417 as reported by European Clinical Trials Database record.
- 14 Jul 2012 Actual initiation date changed from 23 Jul 2010 to 15 Oct 2010 and primary endpoint added as reported by European Clinical Trials Database record.